文献速递神经肿瘤

生长激素分泌型腺瘤最大范围切除联合药物治疗的最终结局

Final Outcome in Growth Hormone-Secreting Adenomas After Combination of Maximal Tumor Resection and Medical Treatment.
PubMed 文献 · World Neurosurg · 2021-07-09

该回顾性研究分析了2002至2017年间120例肢端肥大症患者,评估肿瘤切除范围与残留肿瘤药物治疗对生化缓解的影响。结果显示经鼻内镜入路缓解率显著高于经蝶显微手术(89.45% vs 67.1%,P<0.01),肿瘤体积大和侵袭性低缓解相关,次全切除后加用药物可获生化缓解者残留肿瘤体积显著更小。

要点

  • 手术切除越积极,最终生化缓解机会越大,无论是否达全切除。
  • 经鼻内镜入路生化缓解率显著高于经蝶显微手术。
  • 侵袭性大腺瘤不宜全切者,宜安全次全切除联合药物治疗。

核心结论

  • 手术切除越积极最终生化缓解机会越大,无论是否达全切除。
  • 次全切除者药物治疗效果增强。
  • 侵袭性生长激素大腺瘤不宜全切者,宜安全次全切除联合药物治疗。

研究设计与样本

  • 回顾性分析2002至2017年手术的肢端肥大症患者。
  • 共120例,82例行经蝶显微手术,38例行经鼻内镜入路。
  • 残留肿瘤不宜再次手术者开始药物治疗。
  • 分析垂体腺瘤残留体积与最终生化结局的关系。

主要发现

  • 全切除72例(60%),次全切除21例(17.5%),部分切除27例(22.5%)。
  • 经鼻内镜入路全切除/次全切除率较高但无统计学意义。
  • 经鼻内镜入路缓解率显著更高(89.45% vs 67.1%,P<0.01)。
  • 肿瘤体积更大和侵袭性与较低缓解相关(P<0.05)。
  • 残留肿瘤加药物治疗达生化缓解者肿瘤体积显著更小(P<0.001)。

临床怎么用

  • 对生长激素分泌型腺瘤应争取积极手术切除以增加生化缓解机会。
  • 侵袭性大腺瘤不宜全切时,采用安全次全切除联合药物治疗。
  • 次全切除后加用药物可提高生化缓解可能性。

局限性

  • 为回顾性分析,证据等级有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gross total resection (GTR) is not always possible in acromegalic patients, especially in patients with invasive growth hormone-secreting adenomas. We analyzed the biochemical remission outcome in relation to extent of tumor resection and effectiveness of medical treatment in cases of remnant tumor. METHODS: Retrospective analysis was performed of acromegalic patients operated on between 2002 and 2017. Preoperative imaging, tumor invasiveness, extent of resection, and biochemical remission were collected. Patients with tumor remnant not amenable to second surgery began medical treatment. The relationship between pituitary adenoma remnant volume and final biochemical outcome was analyzed. RESULTS: Of 120 acromegalic patients operated on, 82 underwent transsphenoidal microsurgery and 38 underwent endonasal endoscopic approach. GTR was achieved in 72 cases (60%); subtotal resection (STR), 21 (17.5%) cases; and partial resection, 27 (22.5%) cases. There was a nonsignificant higher rate of GTR/STR in patients who underwent endonasal endoscopic approach. However, a significantly higher remission rate (89.45% vs. 67.1%) was achieved in these patients (P < 0.01). Greater tumor volume and invasiveness were associated with a lower remission (P < 0.05). Patients with tumor remnant who achieved biochemical remission with added medical therapy had a significantly smaller tumor volume (P < 0.001). CONCLUSIONS: The more aggressive surgical resection is, the greater the chance of attaining final biochemical remission, whether or not GTR is achieved. Medical therapy effectiveness is enhanced in cases with STR. Invasive growth hormone-secreting macroadenomas that are not surgically amenable to total resection are best managed with a combination of safe STR and medical treatment.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Torres A, Sanmillan JL, Lau R, et al. Final Outcome in Growth Hormone-Secreting Adenomas After Combination of Maximal Tumor Resection and Medical Treatment. World Neurosurg. 2021. PMID: 34252630. doi:10.1016/j.wneu.2021.07.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。